

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 14607

Title: NEW STRATEGIES OF GENE THERAPY FOR HEPATIC FIBROSIS

Reviewer's code: 02861302

Reviewer's country: Greece

Science editor: Jing Yu

Date sent for review: 2014-10-15 12:20

Date reviewed: 2014-11-11 23:11

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Duplicate publication	publication
<input type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	language polishing	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The authors provide an overview of the main strategies used in gene therapy for liver fibrosis. Although this manuscript is rich in content and generally updated as far as literature is concerned, there are some concerns mainly regarding its structure. For example, it is not clear to the reader that the text is divided in three main parts: 1. NON-VIRAL VECTORS divided into DNA PLASMIDS and LIPOSOMES, 2. VIRAL VECTORS divided into ADENOVIRUSES-BASED SHUTTLE VECTORS, AAV VECTORS and NOVEL VIRAL VECTORS FOR GENE THERAPY and finally 3. BLOCKING MOLECULES FOR INHIBITION OF DELETERIOUS GENES. Additionally, I would appreciate the authors' response to the following comments: Please check and correct references 5-14 according to their order in the text. Reference 52 is missing & Eun-Joong et, al. and Jinxia L, et.al are not mentioned in the references. Please, correct. In the section "non viral vectors", I would suggest quoting references for the methods which are not analyzed thoroughly, i.e. polymers. In the section "DNA plasmids", there appears to be a need for a small introduction about DNA plasmids similar to the introductions used for the rest strategies you deal with. The title "(AUGMENTATION OF LIVER REGENERATION ALR)" is redundant. MMP13 is mentioned amongst the therapy targets in



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

the design of anti-fibrotic strategies for chronic liver diseases but is not analyzed as MMP1, MMP8, MMP9. The section "DECOY MOLECULES" should be incorporated in "BLOCKING MOLECULES FOR INHIBITION OF DELETERIOUS GENES", amongst ANTISENSE OLIGONUCLEOTIDES, siRNA, and miRNAs with a general introduction about new gene therapy approaches based on short DNA or RNA technology. The advantages and disadvantages of gene therapies mentioned here, as well as the potential effectiveness of gene therapy for liver fibrosis in humans should be addressed in the discussion section of the manuscript. Furthermore, the authors could explore whether there is progress in research overcoming the side effects of application of gene therapy in the clinical practice. Conclusively, the manuscript could be organized better and more attention should be given in syntax, spelling and grammar, for successful publication.